In Vitro Activity of Quinupristin/dalfopristin Against Erythromycin-susceptible and Erythromycin-resistant Streptococcus Pneumoniae

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1998 Dec 1

PMID 9832271

Citations 3

Authors

R R Reinert

M Kresken

V Mechery

M Lemperle

R Lutticken

Affiliations

Soon will be listed here.

Abstract

Minimal inhibitory concentrations (MICs) of quinupristin/dalfopristin, penicillin, erythromycin, and clindamycin were determined by a standard agar dilution method for 93 Streptococcus pneumoniae strains isolated from patients with invasive disease in Germany. Quinupristin/dalfopristin showed good activity against 32 penicillin-susceptible/erythromycin-susceptible strains (MIC90 0.5 mg/l; range 0.25-0.5 mg/l) and 31 penicillin-intermediate/erythromycin-susceptible strains (MIC90 0.5 mg/l; range 0.25-1 mg/l). Erythromycin-resistant strains (n=30) were slightly less susceptible (MIC90 1 mg/l; range 0.125-2 mg/l). Quinupristin/dalfopristin was bactericidal (99.9% killing) for all six strains investigated after 2 h at a concentration of 4 mg/l.

Citing Articles

Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Van Bambeke F, Reinert R, Appelbaum P, Tulkens P, Peetermans W Drugs. 2007; 67(16):2355-82.

PMID: 17983256 DOI: 10.2165/00003495-200767160-00005.

Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials.

Reinert R, von Eiff C, Kresken M, Brauers J, Hafner D, Al-Lahham A J Clin Microbiol. 2001; 39(5):1928-31.

PMID: 11326015 PMC: 88050. DOI: 10.1128/JCM.39.5.1928-1931.2001.

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Lamb H, Figgitt D, Faulds D Drugs. 2000; 58(6):1061-97.

PMID: 10651391 DOI: 10.2165/00003495-199958060-00008.

References

Sutcliffe J, Tait-Kamradt A, Wondrack L . Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996; 40(8):1817-24. PMC: 163423. DOI: 10.1128/AAC.40.8.1817. View

Yourassowsky E, Linden M, Crokaert F . Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae. Antimicrob Agents Chemother. 1992; 36(1):46-9. PMC: 189223. DOI: 10.1128/AAC.36.1.46. View

Pankuch G, Lichtenberger C, Jacobs M, Appelbaum P . Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother. 1996; 40(7):1653-6. PMC: 163390. DOI: 10.1128/AAC.40.7.1653. View

Spangler S, Jacobs M, Appelbaum P . Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1992; 36(4):856-9. PMC: 189460. DOI: 10.1128/AAC.36.4.856. View

Fremaux A, Sissia G, Cohen R, Geslin P . In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother. 1992; 30 Suppl A:19-23. DOI: 10.1093/jac/30.suppl_a.19. View

Yourassowsky E, Linden M, Crokaert F . Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Chemotherapy. 1992; 38(1):7-13. DOI: 10.1159/000238935. View

Reinert R, Queck A, Kaufhold A, Kresken M, Lutticken R . Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clin Infect Dis. 1995; 21(6):1398-401. DOI: 10.1093/clinids/21.6.1398. View

Pankuch G, Jacobs M, Appelbaum P . Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994; 38(9):2065-72. PMC: 284685. DOI: 10.1128/AAC.38.9.2065. View

Klugman K . Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990; 3(2):171-96. PMC: 358150. DOI: 10.1128/CMR.3.2.171. View

10.

Barry A, Fuchs P, Brown S . Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother. 1997; 39 Suppl A:87-92. DOI: 10.1093/jac/39.suppl_1.87. View

11.

Neu H, Chin N, Gu J . The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother. 1992; 30 Suppl A:83-94. DOI: 10.1093/jac/30.suppl_a.83. View

12.

Barakett V, Lesage D, Delisle F, Richard G, Petit J . Killing kinetics of imipenem against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1994; 33(5):1025-8. DOI: 10.1093/jac/33.5.1025. View

13.

Bouanchaud D . In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother. 1992; 30 Suppl A:95-9. DOI: 10.1093/jac/30.suppl_a.95. View